Ratio Therapeutics Welcomes Dr. Noel Monks as New Head of Biology

Ratio Therapeutics Inc., a pioneering pharmaceutical company dedicated to developing targeted radiotherapeutics for cancer treatment, is delighted to welcome Dr. Noel Monks as its new Head of Biology. Dr. Monks brings with him an impressive track record of two decades in the oncology and rare diseases drug discovery and development fields, as well as a deep expertise in translational medicine. Ratio is thrilled to have such a talented and experienced leader on board to help further its mission of improving cancer treatment outcomes.

We are delighted to welcome Noel to our team of leading experts in radiopharmaceuticals discovery and development! His expertise in preclinical drug discovery and development will be invaluable as we look to advance Ratio’s pipeline candidates to clinical studies. Noel’s presence will help us further develop our proprietary radiotherapeutic platforms, Trillium™ and Macropa™, and create new partnerships with pharmaceutical companies in the cancer therapy space. With Noel on board, we are confident that we will succeed in our mission to improve cancer care.

Dr. Monks brings a wealth of experience in preclinical biology and pharmacology to Ratio, having previously served as Senior Director of Preclinical Biology and Pharmacology at NeuBase Therapeutics and Associate Director at AstraZeneca/Medimmune. With his expertise, he has been able to successfully lead in vitro and in vivo pharmacology teams and develop comprehensive IND-enabling preclinical data packages for a wide range of projects and therapeutic modalities, including biotherapeutics, small molecules, cell therapies, and genetic medicines.

I feel incredibly lucky and enthusiastic to be joining Ratio as the company embarks on a thrilling new venture: transitioning into the clinical stages of development for its innovative technologies. With my knowledge, enthusiasm, and passion, I look forward to being part of this groundbreaking journey.

Dr. Monks is a highly accomplished academic, having earned a Ph.D. in Cancer Pharmacology and Drug Development from the University of Newcastle upon Tyne, U.K. His expertise in this field has enabled him to make significant advancements in the battle against cancer.

About Ratio Therapeutics

Ratio Therapeutics is on a mission to revolutionize the way we treat solid tumors by developing next-generation precision radiopharmaceuticals. Led by founders John Babich, Ph.D., and Jack Hoppin, Ph.D., the Boston-based pharmaceutical company is home to a growing team of radiopharmaceuticals discovery and development experts with impressive industry experience. Ratio’s proprietary R&D platforms, Trillium™ and Macropa™, facilitate the imaging, discovery and advancement of novel radiopharmaceuticals with superior delivery, safety and efficacy properties. Working in collaboration with Bayer and Lantheus, Ratio is set to revolutionize treatment paradigms for cancer and open the door to multiple new options for those in need.

Leave a Comment